Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
Trial Timeline
Aug 18, 2022 → Feb 7, 2025
NCT ID
NCT05483933About Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154
Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154 is a phase 1 stage product being developed by Shattuck Labs for Platinum-resistant Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05483933. Target conditions include Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05483933 | Phase 1 | Completed |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer